Last reviewed · How we verify

Combined aspirin and multinutrient supplement

UMC Utrecht · Phase 3 active Small molecule

Aspirin reduces platelet aggregation and inflammation while multinutrients provide essential vitamins and minerals to support cardiovascular health and metabolic function.

Aspirin reduces platelet aggregation and inflammation while multinutrients provide essential vitamins and minerals to support cardiovascular health and metabolic function. Used for Cardiovascular disease prevention (phase 3 indication under investigation).

At a glance

Generic nameCombined aspirin and multinutrient supplement
SponsorUMC Utrecht
Drug classAntiplatelet agent combined with nutritional supplement
TargetCOX-1/COX-2 (aspirin); multiple micronutrient targets (multinutrient component)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing thromboxane A2 production and platelet activation to prevent thrombotic events. The multinutrient component supplies cofactors and micronutrients (such as B vitamins, vitamin D, and minerals) that support endothelial function, homocysteine metabolism, and overall cardiovascular protection.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: